SCHEMBL7417166

SCHEMBL7417166

O=C(CC(NC(=O)c1ccccc1)c1ccccc1)NO

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.64
KMT2A Q03164 4/20 0.64
LMNA P02545 4/20 0.60
MAPT P10636 2/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
KDM4E B2RXH2 1/20 0.54
GAA P10253 1/20 0.54
RPS6KA5 O75582 3/20 0.49
AKT1 P31749 3/20 0.49
GSK3B P49841 3/20 0.49
NEK4 P51957 3/20 0.49
PRKCD Q05655 3/20 0.49
PRKG2 Q13237 3/20 0.49
ROCK1 Q13464 3/20 0.49
PRKG1 Q13976 3/20 0.49
PKN2 Q16513 3/20 0.49
CLK4 Q9HAZ1 3/20 0.49
MAPK13 O15264 2/20 0.49
ROCK2 O75116 2/20 0.49
MAP4K4 O95819 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7415740 0.86 EPHX2 (0.54) MEN1KMT2ALMNAMAPTSMN1; SMN2
SCHEMBL22995641 0.85 MEN1 (0.61) MEN1KMT2ALMNAMAPTSMN1; SMN2
SCHEMBL5027698 0.85 MEN1 (0.61) MEN1KMT2ALMNAMAPTSMN1; SMN2
SCHEMBL3717471 0.85 MEN1 (0.61) MEN1KMT2ALMNAMAPTSMN1; SMN2
SCHEMBL30075239 0.84 MEN1 (0.55) MEN1KMT2ALMNAMAPTSMN1; SMN2
SCHEMBL30898781 0.84 MEN1 (0.55) MEN1KMT2ALMNAMAPTSMN1; SMN2
SCHEMBL14327771 0.83 MEN1 (0.59) MEN1KMT2ALMNAMAPTSMN1; SMN2
SCHEMBL27553133 0.82 MEN1 (0.66) MEN1KMT2ALMNAMAPTSMN1; SMN2
SCHEMBL2777735 0.80 ROCK2 (0.70) MEN1KMT2ALMNAKDM4EGAA
SCHEMBL9293287 0.80 ROCK2 (0.70) MEN1KMT2ALMNAKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6218389-B1 FOR THERAPY AND PROPHYLAXIS OF ARTHRITIS, CANCER, CARDIOVASCULAR DISORDERS; SKIN DISORDERS; OCULAR DISORDERS; INFLAMMATION AND GUM DISEASES, MULTIPLE SCLEROSIS, CACHEXIA, PREVENTING LOOSENING OF PROSTHETIC DEVICES THE PROCTER & GAMBLE CO. 2001-04-17 US disclosed
CN-1265647-A Acyclic metalloprotease inhibitors PROCTER & GAMBLE (US) 2000-09-06 CN disclosed
EP-1009737-A2 SULFONYLAMINO SUBSTITUTED HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2000-06-21 EP disclosed
WO-1999006340-A2 SULFONYLAMINO SUBSTITUTED HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 1999-02-11 WO disclosed